Carl Zeiss Meditec : achieves significant growth in revenue and profit in fiscal year 2018/19
October 02, 2019 at 03:20 am EDT
Share
DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Annual Results
Carl Zeiss Meditec AG achieves significant growth in revenue and profit in fiscal year 2018/19
02-Oct-2019 / 09:13 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Carl Zeiss Meditec AG achieves significant growth in revenue and profit in fiscal year 2018/19
Jena, October 2, 2019
Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of approximately EUR 1,459 million in fiscal year 2018/19 (PY: EUR 1,280.9 million), based on preliminary data, and has thereby significantly exceeded the previous forecast of EUR 1,350 to EUR 1,420 million. This corresponds to revenue growth of approximately 13.9% vs. the previous year's value. After adjustment for currency effects[1], growth amounts to around 11.9 %.
From today's point of view, the company expects a strong increase in operating earnings[2] (EBIT) and anticipates to significantly exceed the previous forecast of an EBIT margin[3] between 15.0% to 17.5% (PY: 15.4%) as well as current market expectations estimated at around 18.5%.
Full results for business year 2018/19 will be provided on Dec 6, 2019.
As already reported after nine months 2018/19, management expects no further sustainable increase in EBIT margin in fiscal year 2019/20, partly due to planned strategic investments in research and development.
Contact for investors and press
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: investors.meditec@zeiss.com
[1] Currency-adjusted sales growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates. [2] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2017/18, p. 76 for reconciliation). [3] Calculation: EBIT margin = EBIT / revenue (in %) (see Annual Report 2017/18, p. 76).
02-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena
Germany
Phone:
+49 (0)3641 220-0
Fax:
+49 (0)3641 220-112
E-mail:
investors.meditec@zeiss.com
Internet:
www.zeiss.de/meditec-ag/ir
ISIN:
DE0005313704
WKN:
531370
Indices:
MDAX, TecDAX
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
Carl Zeiss Meditec AG is a Germany-based medical technology and device company. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for microsurgery and other technologies, such as intraoperative radiotherapy. The Company operates in two segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment comprises activities in the area of ophthalmology, such as intraocular lenses, surgical visualization solutions and medical laser and diagnostic systems. The Microsurgery segment includes activities of neuro, ear, nose and throat surgery, as well as the activities in the field of intraoperative radiation. The Company has various production sites in Europe, the United States and Asia.
CARL ZEISS MEDITEC AG 
